Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21366880 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10ELANECTSGEPHX1 | |
| SCHEMBL22968674 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10ELANECTSGEPHX1 | |
| SCHEMBL6534023 | 0.87 | HSD17B10 (0.40) | SMN1; SMN2HSD17B10ELANECTSGPREP | |
| SCHEMBL6534024 | 0.87 | HSD17B10 (0.40) | SMN1; SMN2HSD17B10ELANECTSGPREP | |
| SCHEMBL6534027 | 0.87 | HSD17B10 (0.40) | SMN1; SMN2HSD17B10ELANECTSGPREP | |
| SCHEMBL8349248 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10EPHX1NR1H2NR1H3 | |
| SCHEMBL8441504 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10EPHX1NR1H2NR1H3 | |
| SCHEMBL30591353 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10EPHX1NR1H2NR1H3 | |
| SCHEMBL8349246 | 0.84 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10EPHX1NR1H2NR1H3 | |
| SCHEMBL8304379 | 0.83 | EPHX1 (0.35) | SMN1; SMN2HSD17B10EPHX1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| WO-2004092162-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | SMN1; SMN2 1405/4885HSD17B10 1534/4885ELANE 48/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | SMN1; SMN2 1362/4885HSD17B10 1394/4885ELANE 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.